Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Reed

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Molecular and Cellular Endocrinology|September 13, 2008
Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3Joanna M Day, Helena J Tutill, Paul A Foster, et al.
Chemmedchem|August 8, 2006
Focused libraries of 16-substituted estrone derivatives and modified e-ring steroids: inhibitors of 17beta-hydroxysteroid dehydrogenase type 1Nigel Vicker, Harshani R Lawrence, Gillian M Allan, et al.
Journal of Medicinal Chemistry|July 2, 2008
Chiral aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole template: synthesis, absolute configuration, and in vitro activityPaul M Wood, L W Lawrence Woo, Jean-Robert Labrosse, et al.
Journal of Medicinal Chemistry|August 19, 2007
3,17-disubstituted 2-alkylestra-1,3,5(10)-trien-3-ol derivatives: synthesis, in vitro and in vivo anticancer activityChristian Bubert, Mathew P Leese, Mary F Mahon, et al.
Anticancer Research|May 30, 2008
A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancerPaul A Foster, Simon P Newman, Mathew P Leese, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitorPaul A Foster, Surinder K Chander, Simon P Newman, et al.
Journal of Medicinal Chemistry|September 2, 2005
E-ring modified steroids as novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1Delphine S Fischer, Gillian M Allan, Christian Bubert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2008
STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cellsSimon P Newman, Paul A Foster, Chloe Stengel, et al.
Molecular and Cellular Endocrinology|September 9, 2008
The design of novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitorsNigel Vicker, Christopher M Sharland, Wesley B Heaton, et al.
Journal of Medicinal Chemistry|February 17, 2006
Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1Gillian M Allan, Harshani R Lawrence, Josephine Cornet, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Molecular and Cellular Endocrinology|September 13, 2008
Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3Joanna M Day, Helena J Tutill, Paul A Foster, et al.
Chemmedchem|August 8, 2006
Focused libraries of 16-substituted estrone derivatives and modified e-ring steroids: inhibitors of 17beta-hydroxysteroid dehydrogenase type 1Nigel Vicker, Harshani R Lawrence, Gillian M Allan, et al.
Journal of Medicinal Chemistry|July 2, 2008
Chiral aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole template: synthesis, absolute configuration, and in vitro activityPaul M Wood, L W Lawrence Woo, Jean-Robert Labrosse, et al.
Journal of Medicinal Chemistry|August 19, 2007
3,17-disubstituted 2-alkylestra-1,3,5(10)-trien-3-ol derivatives: synthesis, in vitro and in vivo anticancer activityChristian Bubert, Mathew P Leese, Mary F Mahon, et al.
Anticancer Research|May 30, 2008
A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancerPaul A Foster, Simon P Newman, Mathew P Leese, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitorPaul A Foster, Surinder K Chander, Simon P Newman, et al.
Journal of Medicinal Chemistry|September 2, 2005
E-ring modified steroids as novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1Delphine S Fischer, Gillian M Allan, Christian Bubert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2008
STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cellsSimon P Newman, Paul A Foster, Chloe Stengel, et al.
Molecular and Cellular Endocrinology|September 9, 2008
The design of novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitorsNigel Vicker, Christopher M Sharland, Wesley B Heaton, et al.
Journal of Medicinal Chemistry|February 17, 2006
Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1Gillian M Allan, Harshani R Lawrence, Josephine Cornet, et al.
Pageof 8